Home › Acute Myeloid Leukemia › New York
Acute Myeloid Leukemia clinical trials in New York
72 studies for Acute Myeloid Leukemia are looking for participants at sites in New York.
Cities in New York
- New York City51 studies
- Buffalo20 studies
- Queens19 studies
- Rochester18 studies
- Greenburgh17 studies
- The Bronx15 studies
- Staten Island13 studies
- New Rochelle12 studies
- Syracuse6 studies
- Albany3 studies
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Northwell Health/Center for Advanced Medicine, Lake Success
- and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06317649Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- State University of New York at Buffalo, Buffalo
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07007312Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
- University of Rochester Medical Center, Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT01311258A Study of CRD3874-SI in People With Leukemia
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07661095Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- and 9 more
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT05554406Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Roswell Park Cancer Institute, Buffalo
- University of Rochester, Rochester
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Nov 6, 2026 · NCT07437950A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07751991Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Queens Hospital Center, Jamaica
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Stony Brook University Medical Center, Stony Brook
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Roswell Park Comprehensive Cancer Center, Buffalo
- Memorial Sloan Kettering Cancer Center, New York
- New York Presbyterian - Weill Cornell, New York
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06852222Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06484062MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Northwell Health/Center for Advanced Medicine, Lake Success
- and 9 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05564390Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
- Memorial Sloan-Kettering Cancer Center - Hematology Service MSKCC, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07723703Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Rochester Medical Center (URMC), Rochester
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 30, 2026 · NCT05429632Study of REM-422 in Patients With AML or Higher Risk MDS
- Memorial Sloan Kettering, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06297941CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Roswell Park Cancer Institute, Buffalo
- New York University, New York
- New York-Presbyterian / Weill Cornell Medical Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05143996Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Mount Sinai Hospital, New York
- and 5 more
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Oct 28, 2026 · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06672146Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06871410Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, New York
RecruitingPhase 1/2
Ages 16 and older · All sexes · Updated Oct 23, 2026 · NCT07155226A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- Roswell Park Comprehensive Cancer Center, Buffalo
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT06969430A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Up to age 21 · All sexes · Updated Oct 23, 2026 · NCT07012044Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Memorial Sloan- Kettering Cancer Center, New York
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Oct 22, 2026 · NCT06177067A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- Montefiore Medical Center - Moses Campus /ID# 279399, The Bronx
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07581002Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
- Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06533761A Study of Revumenib and Mezigdomide in People With Leukemia
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 20, 2026 · NCT07356154Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Roswell Park Comprehensive Cancer Center, Buffalo
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT06846606Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
- Montefiore Medical Center, The Bronx
RecruitingPhase 1Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT05986240A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Montefiore Medical Center, New York
RecruitingPhase 1/2
30 Days · All sexes · Updated Oct 9, 2026 · NCT04065399A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- University of Rochester, Rochester
RecruitingObservational study
Ages 0 and older · All sexes · Updated Oct 9, 2026 · NCT07154823A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Roswell Park Comprehensive Cancer Center, Buffalo
- New York University Langone Hospital - Long Island, Mineola
- Perlmutter Cancer Center - 34th Street, New York
- and 2 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT04256317A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
- and 1 more
RecruitingPhase 1
Ages 1 and older · All sexes · Updated Oct 6, 2026 · NCT06017258A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Oct 6, 2026 · NCT07392242A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- New York Medical College /ID# 275597, Valhalla
RecruitingPhase 1
6 Months – 17 Years · All sexes · Updated Oct 5, 2026 · NCT07306832A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 18, 2026 · NCT06284486A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- and 11 more
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Weill Cornell, New York
- Clinical Research Allicance, Westbury
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06824168A Telehealth Advance Care Planning Intervention
- University of Rochester, Rochester
Recruiting
Ages 60 and older · All sexes · Updated Sep 11, 2026 · NCT05875805Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Albany Medical Center, Albany
- Montefiore Medical Center - Moses Campus, The Bronx
RecruitingPhase 3
Ages 1 to 25 · All sexes · Updated Sep 4, 2026 · NCT07022678The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- NYU Langone Hospital - Long Island, Mineola
- and 7 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.